# ASTROTECH Corp: financial statements, quarterly

ASTC · Nasdaq · CIK 1001907 · [Technology](/sectors/technology.md) · fiscal year ends Jun 30

Pages: [Overview](/companies/astc.md) · [Financials](/companies/astc/financials.md) · [Filings](/companies/astc/filings.md) · [Insiders](/companies/astc/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/astc/financials.md?period=annual).

## Income statement

| Line item | Unit | Q1 FY2024 (2023-09-30) | Q2 FY2024 (2023-12-31) | Q3 FY2024 (2024-03-31) | Q4 FY2024 (2024-06-30) | Q1 FY2025 (2024-09-30) | Q2 FY2025 (2024-12-31) | Q3 FY2025 (2025-03-31) | Q4 FY2025 (2025-06-30) | Q1 FY2026 (2025-09-30) | Q2 FY2026 (2025-12-31) | Q3 FY2026 (2026-03-31) | Q4 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $k | [425](/filings/0001437749-24-034674.md) | [1,115](/filings/0001437749-25-003833.md) | [50.0](/filings/0001437749-25-016623.md) | [110 d](/filings/0001437749-25-029909.md) | [34.0](/filings/0001437749-25-034858.md) | [261](/filings/0001437749-26-003997.md) | [534](/filings/0001437749-26-026366.md) | [1,049](/filings/0001437749-26-031175.md) | [297](/filings/0001437749-25-034858.md) | [148](/filings/0001437749-26-003997.md) | [343](/filings/0001437749-26-026366.md) | [913](/filings/0001437749-26-031175.md) |
| Cost of revenue | $k | [242](/filings/0001437749-24-034674.md) | [583](/filings/0001437749-25-003833.md) | [42.0](/filings/0001437749-25-016623.md) | [46.0 d](/filings/0001437749-25-029909.md) | [25.0](/filings/0001437749-25-034858.md) | [106](/filings/0001437749-26-003997.md) | [297](/filings/0001437749-26-026366.md) | [146 d](/filings/0001437749-26-031175.md) | [109](/filings/0001437749-25-034858.md) | [140](/filings/0001437749-26-003997.md) | [276](/filings/0001437749-26-026366.md) | [171 d](/filings/0001437749-26-031175.md) |
| Gross profit | $k | [183](/filings/0001437749-24-034674.md) | [532](/filings/0001437749-25-003833.md) | [8.0](/filings/0001437749-25-016623.md) | [28.0 d](/filings/0001437749-25-029909.md) | [9.0](/filings/0001437749-25-034858.md) | [155](/filings/0001437749-26-003997.md) | [237](/filings/0001437749-26-026366.md) | [74.0 d](/filings/0001437749-26-031175.md) | [188](/filings/0001437749-25-034858.md) | [8.0](/filings/0001437749-26-003997.md) | [67.0](/filings/0001437749-26-026366.md) | [(45.0) d](/filings/0001437749-26-031175.md) |
| Research and development | $k | [1,872](/filings/0001437749-24-034674.md) | [1,578](/filings/0001437749-25-003833.md) | [1,708](/filings/0001437749-25-016623.md) | [1,632 d](/filings/0001437749-25-029909.md) | [1,949](/filings/0001437749-25-034858.md) | [2,437](/filings/0001437749-26-003997.md) | [1,989](/filings/0001437749-26-026366.md) | [1,767 d](/filings/0001437749-26-031175.md) | [1,944](/filings/0001437749-25-034858.md) | [1,832](/filings/0001437749-26-003997.md) | [1,435](/filings/0001437749-26-026366.md) | [1,273 d](/filings/0001437749-26-031175.md) |
| Selling, general and administrative | $k | [1,646](/filings/0001437749-24-034674.md) | [2,022](/filings/0001437749-25-003833.md) | [1,833](/filings/0001437749-25-016623.md) | [1,740 d](/filings/0001437749-25-029909.md) | [1,688](/filings/0001437749-25-034858.md) | [2,039](/filings/0001437749-26-003997.md) | [2,115](/filings/0001437749-26-026366.md) | [1,225 d](/filings/0001437749-26-031175.md) | [1,780](/filings/0001437749-25-034858.md) | [2,077](/filings/0001437749-26-003997.md) | [2,085](/filings/0001437749-26-026366.md) | [1,930 d](/filings/0001437749-26-031175.md) |
| Operating income | $k | [(3,335)](/filings/0001437749-24-034674.md) | [(3,068)](/filings/0001437749-25-003833.md) | [(3,533)](/filings/0001437749-25-016623.md) | [(3,344) d](/filings/0001437749-25-029909.md) | [(3,628)](/filings/0001437749-25-034858.md) | [(4,321)](/filings/0001437749-26-003997.md) | [(3,867)](/filings/0001437749-26-026366.md) | [(2,918) d](/filings/0001437749-26-031175.md) | [(3,536)](/filings/0001437749-25-034858.md) | [(3,901)](/filings/0001437749-26-003997.md) | [(3,453)](/filings/0001437749-26-026366.md) | [(3,248) d](/filings/0001437749-26-031175.md) |
| Income tax | $k | [0.0](/filings/0001437749-24-034674.md) | not reported | not reported | not reported | [0.0](/filings/0001437749-24-034674.md) | [0.0](/filings/0001437749-26-003997.md) | not reported | not reported | not reported | [0.0](/filings/0001437749-26-003997.md) | not reported | not reported |
| Net income | $k | [(2,912)](/filings/0001437749-25-016623.md) | [(2,641)](/filings/0001437749-25-016623.md) | [(3,154)](/filings/0001437749-25-016623.md) | [(2,959) d](/filings/0001437749-25-029909.md) | [(3,278)](/filings/0001437749-26-026366.md) | [(4,009)](/filings/0001437749-26-026366.md) | [(3,633)](/filings/0001437749-26-026366.md) | [(2,930) d](/filings/0001437749-26-031175.md) | [(3,465)](/filings/0001437749-26-026366.md) | [(3,927)](/filings/0001437749-26-026366.md) | [(3,768)](/filings/0001437749-26-026366.md) | [(3,266) d](/filings/0001437749-26-031175.md) |
| Diluted EPS | $ per share | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Basic EPS | $ per share | [(1.79)](/filings/0001437749-24-034674.md) | [(1.62)](/filings/0001437749-25-003833.md) | [(1.93)](/filings/0001437749-25-016623.md) | not reported | [(2.01)](/filings/0001437749-25-034858.md) | [(2.45)](/filings/0001437749-26-003997.md) | [(2.18)](/filings/0001437749-26-026366.md) | not reported | [(2.07)](/filings/0001437749-25-034858.md) | [(2.34)](/filings/0001437749-26-003997.md) | [(2.25)](/filings/0001437749-26-026366.md) | not reported |

- Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax, us-gaap:Revenues
- Cost of revenue: us-gaap:CostOfRevenue
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: not reported
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q1 FY2024 (2023-09-30) | Q2 FY2024 (2023-12-31) | Q3 FY2024 (2024-03-31) | FY2024 (2024-06-30) | Q1 FY2025 (2024-09-30) | Q2 FY2025 (2024-12-31) | Q3 FY2025 (2025-03-31) | FY2025 (2025-06-30) | Q1 FY2026 (2025-09-30) | Q2 FY2026 (2025-12-31) | Q3 FY2026 (2026-03-31) | FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | [3.1](/filings/0001437749-26-031175.md) | not reported | not reported | [2.7](/filings/0001437749-26-026366.md) | [8.4](/filings/0001437749-26-031175.md) |
| Current assets | $m | [41.8](/filings/0001437749-23-031659.md) | [40.1](/filings/0001437749-24-003922.md) | [37.5](/filings/0001437749-24-016375.md) | [34.7](/filings/0001437749-25-029909.md) | [31.6](/filings/0001437749-24-034674.md) | [28.2](/filings/0001437749-25-003833.md) | [24.6](/filings/0001437749-25-016623.md) | [22.0](/filings/0001437749-26-031175.md) | [18.2](/filings/0001437749-25-034858.md) | [14.3](/filings/0001437749-26-003997.md) | [11.3](/filings/0001437749-26-026366.md) | [15.9](/filings/0001437749-26-031175.md) |
| Total assets | $m | [44.6](/filings/0001437749-23-031659.md) | [42.8](/filings/0001437749-24-003922.md) | [40.2](/filings/0001437749-24-016375.md) | [37.6](/filings/0001437749-25-029909.md) | [34.4](/filings/0001437749-24-034674.md) | [31.0](/filings/0001437749-25-003833.md) | [27.5](/filings/0001437749-25-016623.md) | [27.0](/filings/0001437749-26-031175.md) | [23.2](/filings/0001437749-25-034858.md) | [19.7](/filings/0001437749-26-003997.md) | [16.2](/filings/0001437749-26-026366.md) | [20.5](/filings/0001437749-26-031175.md) |
| Current liabilities | $m | [2.2](/filings/0001437749-23-031659.md) | [2.3](/filings/0001437749-24-003922.md) | [2.4](/filings/0001437749-24-016375.md) | [2.5](/filings/0001437749-25-029909.md) | [2.1](/filings/0001437749-24-034674.md) | [2.6](/filings/0001437749-25-003833.md) | [2.5](/filings/0001437749-25-016623.md) | [2.5](/filings/0001437749-26-031175.md) | [1.9](/filings/0001437749-25-034858.md) | [1.9](/filings/0001437749-26-003997.md) | [1.8](/filings/0001437749-26-026366.md) | [2.3](/filings/0001437749-26-031175.md) |
| Total liabilities | $m | [2.5](/filings/0001437749-23-031659.md) | [2.6](/filings/0001437749-24-003922.md) | [2.6](/filings/0001437749-24-016375.md) | [2.8](/filings/0001437749-25-029909.md) | [2.4](/filings/0001437749-24-034674.md) | [2.9](/filings/0001437749-25-003833.md) | [2.7](/filings/0001437749-25-016623.md) | [4.9](/filings/0001437749-26-031175.md) | [4.2](/filings/0001437749-25-034858.md) | [4.2](/filings/0001437749-26-003997.md) | [4.0](/filings/0001437749-26-026366.md) | [4.3](/filings/0001437749-26-031175.md) |
| Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Current portion of debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [42.1](/filings/0001437749-25-016623.md) | [40.3](/filings/0001437749-25-016623.md) | [37.6](/filings/0001437749-25-016623.md) | [34.8](/filings/0001437749-26-031175.md) | [32.1](/filings/0001437749-26-026366.md) | [28.1](/filings/0001437749-26-026366.md) | [24.8](/filings/0001437749-26-026366.md) | [22.1](/filings/0001437749-26-031175.md) | [19.1](/filings/0001437749-26-026366.md) | [15.5](/filings/0001437749-26-026366.md) | [12.2](/filings/0001437749-26-026366.md) | [16.2](/filings/0001437749-26-031175.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: not reported
- Current portion of debt: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q1 FY2024 (2023-09-30) | Q2 FY2024 (2023-12-31) | Q3 FY2024 (2024-03-31) | Q4 FY2024 (2024-06-30) | Q1 FY2025 (2024-09-30) | Q2 FY2025 (2024-12-31) | Q3 FY2025 (2025-03-31) | Q4 FY2025 (2025-06-30) | Q1 FY2026 (2025-09-30) | Q2 FY2026 (2025-12-31) | Q3 FY2026 (2026-03-31) | Q4 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [(3,050)](/filings/0001437749-24-034674.md) | [(1,800) d](/filings/0001437749-25-003833.md) | [(2,342) d](/filings/0001437749-25-016623.md) | [(2,533) d](/filings/0001437749-25-029909.md) | [(3,686)](/filings/0001437749-25-034858.md) | [(3,044) d](/filings/0001437749-26-003997.md) | [(3,861) d](/filings/0001437749-26-026366.md) | [(2,361) d](/filings/0001437749-26-031175.md) | [(3,936)](/filings/0001437749-25-034858.md) | [(3,543) d](/filings/0001437749-26-003997.md) | [(3,686) d](/filings/0001437749-26-026366.md) | [(2,288) d](/filings/0001437749-26-031175.md) |
| Capital expenditure | $k | [24.0](/filings/0001437749-24-034674.md) | [153 d](/filings/0001437749-25-003833.md) | [176 d](/filings/0001437749-25-016623.md) | [226 d](/filings/0001437749-25-029909.md) | [193](/filings/0001437749-25-034858.md) | [319 d](/filings/0001437749-26-003997.md) | [(27.0) d](/filings/0001437749-26-026366.md) | [348 d](/filings/0001437749-26-031175.md) | [448](/filings/0001437749-25-034858.md) | [411 d](/filings/0001437749-26-003997.md) | [(2.0) d](/filings/0001437749-26-026366.md) | [22.0 d](/filings/0001437749-26-031175.md) |
| Share repurchases | $k | not reported | not reported | not reported | [0.0 d](/filings/0001437749-24-029650.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q1 FY2012 (2011-09-30) | Q2 FY2012 (2011-12-31) | Q3 FY2012 (2012-03-31) | Q1 FY2013 (2012-09-30) | Q2 FY2013 (2012-12-31) | Q3 FY2013 (2013-03-31) | Q1 FY2014 (2013-09-30) | Q2 FY2014 (2013-12-31) | Q3 FY2014 (2014-03-31) | Q1 FY2015 (2014-09-30) | Q2 FY2015 (2014-12-31) | Q3 FY2015 (2015-03-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [0.0](/filings/0001515971-12-000406.md) | [18.4](/filings/0001515971-13-000053.md) | [19.2](/filings/0001515971-13-000224.md) | [19.0](/filings/0001515971-13-000548.md) | [19.4](/filings/0001515971-14-000051.md) | [19.5](/filings/0001571049-14-001849.md) | [19.5](/filings/0001571049-14-006393.md) | [0.0](/filings/0001571049-15-001205.md) | [19.5](/filings/0001628280-15-004032.md) | [19.5](/filings/0001571049-14-006393.md) | [0.0](/filings/0001571049-15-001205.md) | [19.5](/filings/0001628280-15-004032.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 2,009,050 at 2026-09-23, from the cover of the [10-K filed 2026-09-25](/filings/0001437749-26-031175.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:29 ET. No prices; not investment advice.